Ad
related to: AstraZeneca
Search results
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 1 day agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
Data Science Hiring Process at AstraZeneca
Analytics India Magazine· 1 day agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 5 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 16 hours agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 21 hours agoThe American Society of Clinical Oncology held its annual conference in Chicago this past week,...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 3 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 2 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 2 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...